Skip to main content

Table 3 Characteristics of ADPKD patients screened for PKD2 mutations. ns = not significant

From: Clinical utility of PKD2 mutation testing in a polycystic kidney disease cohort attending a specialist nephrology out-patient clinic

  Non-PKD2 PKD2 p- value
Number (%) 115 (80.3) 27 (19.7)  
Male:female 0.59 0.59  
Age at clinic presentation y 49.0 ± 13.3 49.5 ± 14.8 ns
Age at diagnosis y 37.4 ± 15.4 42.6 ± 14.4 ns
Hypertensive at diagnosis % 42.6 40.7 ns
Treatment for hypertension % 84.3 70.4 ns
Progression to ESRF % 12.2 0 p < 0.03
eGFR at presentation ml/min/1.73 m2 67.0 ± 27.6 74.0 ± 28.4 ns
No FH of ADPKD % 35.6 25.9 ns
FH with ESRF % 50.4 40.7 ns
FH with no ESRF % 13.9 33.4 p < 0.03
Median age of family member at ESRF y (range) 54.1 (33–83) 65.5 (50–86) p < 0.0001
Number with FH ESRF < 50 yrs 31 0  
Number with FH ESRF < 60 yrs 69 4  
Number with FH ESRF < 70 yrs 81 9  
Number with FH ESRF ≥ 70 yrs 8 6  
Number of family members with ESRF (where age known) 89 15